D. Boral Capital Reaffirms "Buy" Rating for Omeros (NASDAQ:OMER)

Key Points

• D. Boral Capital has reiterated a "buy" rating for Omeros (NASDAQ:OMER) with a target price of $36.00, indicating confidence in the stock's performance.
• Omeros has seen varied ratings from analysts, including a strong buy, buy, hold, and sell ratings, with an average target price of $18.00.
• The company's stock has experienced significant price fluctuations, opening at $4.12 and showcasing a 1-year low of $2.95 and a high of $13.60.

D. Boral Capital reissued their buy rating on shares of Omeros (NASDAQ:OMER - Free Report) in a research note published on Friday,Benzinga reports. The firm currently has a $36.00 price target on the biopharmaceutical company's stock.

Other research analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Omeros from a "hold" rating to a "sell" rating in a research report on Friday, June 27th. HC Wainwright reissued a "buy" rating and set a $9.00 price objective on shares of Omeros in a research report on Friday, June 27th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a report on Friday, May 16th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $18.00.

Omeros Stock Down 3.1%

NASDAQ:OMER traded down $0.1350 on Friday, hitting $4.2250. The stock had a trading volume of 709,303 shares, compared to its average volume of 913,327. The business's 50-day simple moving average is $3.61 and its two-hundred day simple moving average is $5.71. The stock has a market cap of $260.94 million, a price-to-earnings ratio of -2.00 and a beta of 2.26. Omeros has a 52-week low of $2.95 and a 52-week high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.02. The business had revenue of $28.60 million during the quarter, compared to the consensus estimate of $0.31 million. As a group, equities research analysts anticipate that Omeros will post -3.09 EPS for the current year.

Institutional Investors Weigh In On Omeros

Institutional investors have recently added to or reduced their stakes in the stock. B. Riley Wealth Advisors Inc. bought a new stake in shares of Omeros during the second quarter valued at approximately $32,000. Newbridge Financial Services Group Inc. purchased a new position in Omeros during the second quarter valued at $280,000. Tower Research Capital LLC TRC grew its stake in Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company's stock valued at $40,000 after acquiring an additional 11,971 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Omeros by 548.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 25,272 shares of the biopharmaceutical company's stock valued at $76,000 after acquiring an additional 21,376 shares during the last quarter. Finally, Brevan Howard Capital Management LP purchased a new stake in Omeros in the 2nd quarter worth $316,000. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.